Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due to
AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to support post-marketing regulatory requirements for seladelpar's accelerated
Gainers
Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics.